Research Grade Lintuzumab
Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225 Ac]Ac-lintuzumab clinical trials were discussed in detail in reference . Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia) .
Product Specifications
Product Name Alternative
225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195, CAS: 166089-32-3
Accession Number
P20138
Expression System
Mammalian Cells
Reactivity
Human
Applications
Research Grade Biosimilar
Stability
Endotoxin
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Form
Liquid
Buffer
0.01M PBS, pH 7.4.
Notes
For research use only. Not suitable for clinical or therapeutic use.
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Porcine Dentin Matrix Acidic phosphoprotein 1 (DMP1) ELISA Kit
Porcine Dentin Matrix Acidic phosphoprotein 1 (DMP1) ELISA Kit
TRIM49 (Tripartite Motif-containing 49, RING Finger Protein 18, Testis-specific RING Finger Protein, RNF18) (MaxLight 750)